Standout Papers

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations 2018 2026 2020 2023 329
  1. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations (2018)
    Matthew Dankner, April A. N. Rose et al. Oncogene
  2. Neoadjuvant Chemoimmunotherapy for NSCLC (2024)
    Mark Sorin, Connor Prosty et al. JAMA Oncology

Citation Impact

56 standout
Sub-graph 1 of 23

Citing Papers

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
2024 Standout
2 intermediate papers

Works of Matthew Dankner being referenced

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
2018
CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy
2017

Author Peers

Author PRM Oncology Molecular Biology Last Decade Papers Cites
Matthew Dankner 205 347 366 28 685
Veronika Quaiserová‐Mocko 8 1 54 8 360
J Radvan 42 19 53 14 739
R. Deraedt 26 34 311 27 1.0k
Natasha S. Savage 1 2 701 17 847
Zhuo‐Wei Wang 16 110 17 644

All Works

Loading papers...

Rankless by CCL
2026